Recent studies have hypothesized that GLP-1 agonists are mainly beneficial for COVID-19 patients and have a state of hyper-inflammation along with worse outcomes in people suffering from atherosclerosis, obesity, and T2DM. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.